Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1249 of 5804
-
Farming program aims to cut STI rates in kenyan teens
Prevention Recruiting nowIn Kenya, HIV incidence among adolescent girls and young women (AGYW) ages 15-24 years is 1-2 per 100 person-years and approximately 30% of AGYW have had at least one sexually transmitted infection (STI). Kisumu and Migori counties in Western Kenya have some of the highest HIV/ST…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
New breathing device aims to cut lung infections in bronchiectasis patients
Disease control Recruiting nowThe study will examine how the performance of Oscillating Lung Expansion (OLE) therapy affects the respiratory health of patients with Bronchiectasis (BE). The patient will use the BiWaze Clear system for their airway clearance therapy, instead of their previously prescribed the…
Phase: NA • Sponsor: Delve Health • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can talk therapy beat insomnia and depression in seniors? new study aims to find out.
Symptom relief Recruiting nowThis is a multi-site randomized control trial involving people age 55+ years who have current depression symptoms plus another suicide risk indicator (either current suicidal ideation or a past history of attempt). Our goal is evaluate which of two different approaches works best…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Blood cancer drug pirtobrutinib tested for Long-Term safety in ongoing study
Disease control Recruiting nowStudy J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue…
Phase: PHASE4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for rare stomach cancer: Triple-Drug attack before surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn if treatment modality including Disitamab Vedotin (RC48), Oxaliplatin,Tegafur,Gimeracil and Oteracil Porassium Capsules (SOX)and Sindillimab works to treat locally advanced hepatoid adenocarcinoma of stomach. It will also learn about th…
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 18:14 UTC
-
Sights, sounds, and scents: a new way to soothe ICU patients?
Symptom relief Recruiting nowThe purpose of this study is to assess the impact of adding three sensory elements (visual, auditory, olfactory) on reducing discomfort in patients hospitalized in the intensive care unit/continuing care unit.
Phase: NA • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Killing virus joins forces with immunotherapy in new trial
Disease control Recruiting nowThe purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients.…
Phase: PHASE1 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Heart drug pelacarsen moves to Long-Term safety check in 600 patients
Disease control Recruiting nowThis non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo may be safer for elderly heart patients after stenting
Disease control Recruiting nowThe OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and safety of indobufen-based dual antiplatelet therapy…
Phase: PHASE4 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Lullabies may boost brain power in preterm infants, new study suggests
Knowledge-focused Recruiting nowThe investigators are conducting a two-site randomized control trial with the aim of defining the impact of music (M) without or with parent voice (MPV) on very preterm infants' acute and cumulative stress, intranetwork connectivity on term brain MRI, and language and other neuro…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New hope for stubborn arthritis: experimental drug targets immune cells
Disease control Recruiting nowA Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a vitamin help kids with autism? new trial tests folinic acid
Symptom relief Recruiting nowAutism spectrum disorder (ASD) is a neurodevelopmental condition that affects communication, behavior, and social interaction in children. Current treatments are limited and mainly focus on managing symptoms. This study aims to evaluate whether folinic acid is safe and effective …
Phase: PHASE2 • Sponsor: KK Women's and Children's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Can a shot help people with high IgE eat more foods safely?
Disease control Recruiting nowIn this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen …
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could your muscle type predict diabetes? scientists launch Long-Term investigation
Knowledge-focused Recruiting nowInsulin resistance is an early etiological factor in the development of type-2 diabetes (T2D), which constitutes a large societal health burden with an expected additional rise in the years to come. Skeletal muscle is the body's largest lean tissue mass and the major site of glu…
Sponsor: University Ghent • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
One patient, one custom drug: a bold experiment for a rare syndrome
Disease control OngoingThis research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Bainbridge-Ropers Syndrome (BRPS) due to a pathogenic, de novo nonsense variant in ASXL3
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could a laser switch reduce eye injections for severe Diabetes-Related vision loss?
Disease control Recruiting nowThe macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO). In DMO, fluid leaks from blood vessels and builds up at the macula, causing sight loss. DMO can be mild or severe; this is deter…
Phase: PHASE3 • Sponsor: Belfast Health and Social Care Trust • Aim: Disease control
Last updated Jun 26, 2026 19:03 UTC
-
Your voice may reveal Alzheimer's: new app tested for diagnosis
Diagnosis CompletedThe goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD …
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Diagnosis
Last updated Jun 27, 2026 08:10 UTC
-
Nasal spray could tame brain inflammation in rare neurological disease
Disease control Recruiting nowA Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
Phase: PHASE2 • Sponsor: Tiziana Life Sciences LTD • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Can lupus kidney patients stop treatment? new study tests ianalumab withdrawal
Disease control Recruiting nowThe purpose of this up to 6-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response \[CRR\] or partial renal response \[PRR\]) on double-blind treat…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat colorectal cancer
Disease control TerminatedThis is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (WD-01) in the metastatic colorectal cancer.
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC